Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials

European Journal of Cancer

Volumn 49, Issue 4, 2013, Pages 769-781

  Bellera, Carine A ^a,b,l   Pulido, Marina ^a,b,l   Gourgou, Sophie ^c   Collette, Laurence ^d   Doussau, Adélaïde ^b,e,f   Kramar, Andrew ^g   Dabakuyo, Tienhan Sandrine ^h   Ouali, Monia ^d   Auperin, Anne ⁱ   Filleron, Thomas ^j   Fortpied, Catherine ^d   Le Tourneau, Christophe ^k   Paoletti, Xavier ^k   Mauer, Murielle ^d   Mathoulin Pélissier, Simone ^a,b,f,l   Bonnetain, Franck ^l,m  

^a INSTITUT BERGONIÉ   (France)

^b Centre of Clinical Investigation Clinical Epidemiology   (France)

^c CENTRE VAL D AURELLE   (France)

^d EORTC DATA CENTER   (Belgium)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ DE BORDEAUX   (France)

^g CENTRE OSCAR LAMBRET   (France)

^h CENTRE GEORGES FRANÇOIS LECLERC   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j INSTITUT CLAUDIUS REGAUD   (France)

^k INSERM U900   (France)

^l CTD INCa   (France)

^m UNIVERSITY HOSPITAL OF BESANÇON   (France)

more..

Author keywords

Clinical protocol; Clinical trial surrogate endpoints; Endpoint definitions; Guidelines as topic; Survival analysis

Indexed keywords

ARTICLE; BREAST CANCER; CANCER LOCALIZATION; CLINICAL PROTOCOL; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HUMAN; METHODOLOGY; PANCREAS CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDIZATION; STRUCTURED QUESTIONNAIRE;

CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; RESEARCH DESIGN; SURVIVAL RATE; TIME FACTORS;

EID: 84873707369     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.09.035     Document Type: Article

References (20)

1. R. Pazdur Endpoints for assessing drug activity in clinical trials Oncologist 13 Suppl. 2 2008 19 21
2. B. Chibaudel, F. Bonnetain, and Q. Shi Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy-an Aide et Recherche en Cancerologie Digestive Group Study J Clin Oncol 29 31 2011 4199 4204
3. C. Le Tourneau, S. Michiels, H.K. Gan, and L.L. Siu Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer J Clin Oncol 27 35 2009 5965 5971
4. S. Mathoulin-Pelissier, S. Gourgou-Bourgade, F. Bonnetain, and A. Kramar Survival end point reporting in randomized cancer clinical trials: a review of major journals J Clin Oncol 26 22 2008 3721 3726
5. J.J. Johnson, G. Williams, and R. Pazdur End points and United States Food and Drug Administration approval of oncology drugs J Clin Oncol 21 7 2003 1404 1411
6. Food and Drug Administration H International Conference on Harmonisation; Guidance on Statistical Principles for Clinical Trials; Availability Fed Regist 63 179 1998 49583 49598
7. K.F. Schulz, D.G. Altman, and D. Moher CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials Ann Intern Med 152 11 2010 726 732
8. H. Birgisson, U. Wallin, L. Holmberg, and B. Glimelius Survival endpoints in colorectal cancer and the effect of second primary other cancer on disease free survival BMC Cancer 11 2011 438
9. E. Van Cutsem, R. Labianca, and G. Bodoky Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3 J Clin Oncol 27 19 2009 3117 3125
10. R.A. Nout, W.E. Fiets, H. Struikmans, F.R. Rosendaal, H. Putter, and J.W. Nortier The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer Breast Cancer Res Treat 109 3 2008 567 572
11. C.J. Punt, M. Buyse, and C.H. Kohne Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials J Natl Cancer Inst 99 13 2007 998 1003
12. J.M. Llovet, A.M. Di Bisceglie, and J. Bruix Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 10 2008 698 711
13. C.A. Hudis, W.E. Barlow, and J.P. Costantino Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system J Clin Oncol 25 15 2007 2127 2132
14. K. Fitch, S.J. Bernstein, and M.D. Aguilar The RAND/UCLA appropriateness method user's manual 2001 RAND Santa Monica
15. Haute Autorité de santé. Bases méthodologiques pour l'élaboration de recommendations professionnelles par consensus formalisé; 2006.
16. B.D. Cheson, B. Pfistner, and M.E. Juweid Revised response criteria for malignant lymphoma J Clin Oncol 25 5 2007 579 586
17. H.I. Scher, S. Halabi, and I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 7 2008 1148 1159
18. J. Jones, and D. Hunter Consensus methods for medical and health services research BMJ 311 7001 1995 376 380
19. H.A. Linstone, and M. Turoff The Delphi method: techniques and applications 1975 Addison-Wesley Pub. Co. Reading, Mass.
20. M.K. Murphy, N.A. Black, and D.L. Lamping Consensus development methods, and their use in clinical guideline development Health Technol Assess 2 3 1998 i 88